Pharma & Bio
Technology
Cha Healthcare’s Merger with ChaCares Ahead of Its IPO… What About Cha Kwang-ryeol and Cha Won-tae’s Stakes? [ChaBio Deep Dive ③]
The merger between Cha Healthcare and Cha Care, which the Cha Bio Group has been pursuing since late 2024, is closely tied to the ownership structure of the founding family. This is because Cha Kwang-…
- 2026-10-26 07:01:02
- KIM SAE-MI
Lifestyle
“Wasn’t Moderna the one that provided the cancer vaccine?”…Domestic treatment to prevent cancer recurrence
A “cancer vaccine” craze is sweeping the global anticancer drug market. This follows Moderna’s demonstration that its personalized mRNA cancer vaccine has the potential to suppress cancer recurrence. …
- 2026-10-26 06:01:02
- KIM JI-WAN
Business·Industry
[ESMO 2026] SillaJen, Inc.: “BAL0891 Demonstrates Disease Control in All Treatment Groups, Both as Monotherapy and in Combination… Complete Response Also Confirmed”
“Bladder cancer patients treated with BAL0891 have maintained treatment for over 18 months and have sustained a response for more than seven months even after achieving complete remission (CR).”
Le…
- 2026-10-25 12:01:02
- Kim Jinsoo
Technology
Baeksite’s ‘31A’ Phase 3 Success… Competition Heats Up Ahead of SK Basa’s ‘21A’ Launch
With Baeksite successfully completing Phase 3 clinical trials for its pneumococcal vaccine “VAX-31” in adults, competition in the pneumococcal vaccine market appears to be intensifying. The vaccine fo…
- 2026-10-25 06:41:02
- KIM SUNG-JIN
Technology
Rokit Healthcare Plunges 20% Following FDA Warning Letter to U.S. Partner [K-bio Pulse]
Korean small-cap pharma, biotech, and healthcare stocks moved in opposite directions on Oct. 22, as large-cap chipmakers weakened. Rokit Healthcare posted the steepest decline on the KOSDAQ, while in-…
- 2026-10-24 06:17:02
- Kim Seung-kwon
Technology
ROKIT HEALTHCARE Inc. Plummets 20% Amid Fallout from U.S. Partner’s FDA Warning Letter [Bio Spotlight]
On the 22nd, while large-cap semiconductor stocks were weak on the domestic stock market, small- and mid-cap pharmaceutical, biotech, and healthcare stocks showed mixed performance. Among the top decl…
- 2026-10-24 06:16:02
- Kim Seung-kwon
Technology
Lemon Hits Limit-Up; Licensing Hopes Boost G2G and OliX [K-Bio Pulse]
South Korean biotech stocks posted strong gains on October 21, with Lemon Healthcare hitting the daily upper price limit despite no clear catalyst. G2GBIO surged on expectations of a potential licensi…
- 2026-10-23 13:02:02
- KIM SAE-MI
Technology
Lemon Healthcare Goes Public… Expectations Rise for Technology Exports to Big Pharma by G2GBIO, Inc. and Olix Pharmaceuticals, Inc. [Bio Spotlight]
On the 21st, in the biotech and healthcare sector, #LemonHealthcare hit the daily price limit, while #G2GBIO, Inc. surged on speculation about a potential technology transfer deal with Novo Nordisk. O…
- 2026-10-23 13:01:02
- KIM SAE-MI
Lifestyle
Is the Efficacy Announcement a “Predetermined Outcome”?… “Some Indicators Point in the Desired Direction”
Aptabio Therapeutics Inc.(293780)has expressed confidence ahead of the announcement of the efficacy of its kidney disease treatment candidate “Isuzinaxib” (APX-115). This follows the company’s selecti…
- 2026-10-23 12:02:02
- KIM JI-WAN
Lifestyle
Dop’s New Venture into Aesthetic Medicine Proves a ‘Huge Success’... Begins in Singapore and Begins Full-Scale Export Operations
DOP, a human tissue-based biotech company, is achieving remarkable results in the aesthetic medicine sector, a new market it has recently entered. “ESSALIA,” an injectable product based on acellular a…
- 2026-10-23 09:31:02
- YU JIN-HEE
PHARM EDAILY
Shorts